Bayer, Schering-Plough in strategic pharmaceuticals alliance
691450
BERLIN -- German chemical and drug maker Bayer AG and New Jersey pharmaceutical company Schering-Plough Corp. announced Monday they have entered a strategic alliance under which Schering-Plough will distribute
245551
Schering-Plough (SGP:NYSE - news - research) Monday announced a broad marketing agreement with Germany&#39;s Bayer (BAY:NYSE - news - research) that both companies said will lead to a more efficient use of their marketing and sales strengths.
627268
By Sharon Smyth  Merck, the German pharmaceutical company that failed to buy a rival, Schering, this year, agreed to buy the stake owned by the billionaire Ernesto Bertarelli in Serono to obtain control of the largest biotechnology company in Europe.
157645
Biotechnology company Rigel  Pharmaceuticals Inc. RIGL.O has entered into a collaboration  pact with drugmaker Merck & Co. Inc. MRK.N to find treatments  for cancer and potentially other diseases, Rigel said on  Monday.
238458
Seeking to improve its drug discovery technology and establish a beachhead in the fertile Cambridge biotechnology cluster, drug giant Schering-Plough Corp. of Kenilworth, N.J., said it would buy NeoGenesis Pharmaceuticals Inc. of Cambridge for an undisclosed sum.
657623
Roche and the US-based biopharmaceutical  company Alnylam Pharmaceuticals, Inc.  on Monday  unveiled a $1 billion alliance giving Roche rights to Alnylam&#39;s  technology for developing so-called RNA interference therapies.
435430
Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies&#39; pharmaceutical resources while maintaining each company&#39;s own strategic interests.
24676
Bayer AG forged an alliance for its struggling pharmaceuticals business with US drugmaker Schering-Plough on Monday, cutting costs and marking another step in the German company&#39;s transformation.
456207
Dutch chemical group Akzo Nobel NV   said on Monday it is selling its  pharmaceutical unit Organon BioSciences to Schering-Plough   for 11 billion euros ($14.5 billion).
377721
Faced with the threat of generic competition, the company focuses its efforts on a new drug.
95723
Drug maker Schering-Plough Corp  on Tuesday reported a fourth-quarter loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales.
274636
Merck and Schering-Plough get together again.
531621
Schering gets an expanded label and begins marketing another drug overseas.
359157
Schering-Plough Corp. paid $435 million in fines and pleaded guilty to criminal conspiracy charges to settle Justice Department accusations that it lied to the government about drug prices and improperly marketed cancer drugs for uses not approved by the Food and Drug Administration.
533746
German stocks advanced, led by Bayer AG, after the company said it formed a marketing partnership with a US competitor. The benchmark DAX Index rose 30.
230439
LONDON (CBS.MW) -- European drugmakers Novartis, Schering and Sanofi-Aventis on Thursday all posted rising third-quarter sales, helped by sales lifts in the companies&#39; key products.
107681
An experimental thrombosis pill from   Bayer AG, seen by analysts as the German group's most important   pipeline asset, has produced promising results in two clinical   trials, researchers said on Tuesday.